Physician profile
Stuart W Larson
NPI 1124178009
$6,888.23
in general payments reported to CMS, 2019-2025
21 companies · $2,757 in 2025
The $2,757 reported for 2025 was more than what 92% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24.04 · 2021: $37.17 · 2022: $265 · 2023: $1,578 · 2024: $2,227 · 2025: $2,757.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,514 · Education: $48.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,513.57 |
| Education | $48.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $863.52 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $820.18 | 2023-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $611.05 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $587.91 | 2021-2025 | Lybalvi, Aristada, Vivitrol |
| Vanda Pharmaceuticals INC. | $500.26 | 2024-2025 | Fanapt |
| Axsome Therapeutics, INC. | $490.96 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $488.25 | 2022-2025 | Invega Sustenna, Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $390.68 | 2022-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $375.86 | 2023-2025 | Qelbree, Qelbree |
| Corium, LLC | $374.37 | 2023-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $347.56 | 2024-2025 | Cobenfy, Coumadin |
| Almatica Pharma LLC | $249.50 | 2023-2025 | Loreev Xr |
| Neurocrine Biosciences, INC. | $203.81 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $172.73 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $125.18 | 2023-2025 | Abilify Maintena, Rexulti |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $77.55 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $76.96 | 2025 | Jornay Pm |
| Biogen, INC. | $51.10 | 2025 | Zurzuvae |
| Idorsia Pharmaceuticals US INC | $41.63 | 2023 | Quviviq |
| Ironshore Pharmaceuticals INC. | $24.04 | 2019 | |
| Noven Therapeutics, LLC | $15.13 | 2025 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.